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Summary
Objective: Cartilage-speciﬁc extracellular matrix (ECM) proteins have been proposed to play key roles in modulating cellular phenotypes
during chondrogenesis of mesenchymal stem cells. Matrilin (MATN)1 and MATN3 are among the most up-regulated ECM proteins during
chondrogenesis. The aim of this study was to analyze their roles in chondrogenesis of mesenchymal ﬁbroblasts from synovium.
Methods: Primary synovial ﬁbroblasts (SFBs) were puriﬁed from porcine synovium and incubated in pellet culture for 18 days. Chondrogen-
esis of SFB was analyzed by histological staining with safranin-O/fast green, and by quantifying glycosaminoglycans (GAG) with dimethyl-
methylene blue assay. The mRNA levels of chondrogenic markers including collagen II, aggrecan, and Sox 9 were quantiﬁed by real-time
reverse transcription polymerase chain reaction, while the protein levels of Col II and MATNs were determined by western blot analysis.
Results: SFBs underwent chondrogenesis after incubation with transforming growth factor-b1 (TGF-b1) for 3 days; however, this process was
attenuated during the subsequent incubation period. Expression of aMatn1 or Matn3 cDNA maintained and further enhanced chondrogenesis
of SFBs as shown by increased cartilaginous matrix areas, elevated amount of GAG, and stimulated expression of chondrogenic markers.
Conclusion: Our ﬁndings suggest a novel function for MATN1 and MATN3 to maintain and enhance chondrogenesis of mesenchymal ﬁbro-
blasts initiated by TGF-b. Our results also support a critical role of cartilage-speciﬁc ECM proteins to modulate cellular phenotypes in the
microenvironment during chondrogenic differentiation.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Key words: Matrilin, Synovium, Mesenchymal stem cells, Chondrogenesis, TGF-b.Introduction
Differentiation of mesenchymal stem cells (MSCs) provides
promise for cell therapy and regenerative medicine1,2. In
addition to bone marrow3,4, MSCs can be isolated from var-
ious adult mesenchymal tissues such as synovium5e7, peri-
osteum8, skeletal muscle7, and adipose tissue9. However, it
is not completely understood how the MSCs from those
tissues initiate, progress, and maintain a particular differen-
tiated cell phenotype.
Compared to other sources, the synovium is an excellent
source of MSCs from the standpoint of utility as well as its
high differentiation ability10e12. Recent studies suggest
that the synovial ﬁbroblast (SFB) is a strong candidate for
chondrogenic differentiation. Studies of the ontogenetic
development of synovial joints have revealed that articular
chondrocytes and synovial cells originate from a common
precursor pool13 and exist in a close functional relationship
not only during fetal development but also in adult life14.1Supported by a Research Grant from the AO Foundation to M.P.
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1110Furthermore, synovial cells have been shown to possess
tremendous chondrogenic potential under various patho-
logical conditions in vivo. For example, synovial chondro-
matosis is observed in disease states in which human
chondroprogenitor cells of synovial origin sustain their
high proliferative potential and capacity to differentiate into
chondrocytes irrespective of the individual’s age5,15,16. Im-
portantly, synovial cells share several properties with chon-
drocytes, including the production of extracellular matrix
(ECM) proteins including cartilage oligomeric matrix protein
(COMP)17e19, link proteins20, and sulfated glycosaminogly-
cans (sGAG)21.
Despite recent progress in MSC research, very little is
known about how SFBs initiate and maintain chondrogenic
progression. Our hypothesis is that the microenvironment
surrounding cells, including both growth factors and ECM,
play an important role in modulating cell phenotypes during
chondrogenic differentiation. In particular, in this study, we
test the relationship between transforming growth factor-
b1 (TGF-b1), which has previously been shown to induce
chondrogenesis of MSCs, and cartilage-speciﬁc ECM
proteins matrilin (MATN)1 and MATN3 in initiating and
maintaining chondrogenesis of SFBs.
MATNs are a family of non-collagenous ECM proteins
consisting of four known members. Among them, MATN1
and MATN3 are expressed speciﬁcally in cartilage.
1111Osteoarthritis and Cartilage Vol. 16, No. 9MATN3 [Fig. 1(A)] is composed of a singleN-terminal vonWil-
lebrand Factor A (vWFA) domain followed by four epidermal
growth factor (EGF) repeats and a coiled-coil domain,
whereas MATN1 [Fig. 1(A)] is composed of two vWFA
domains separated by oneEGF-like domain. Microarray stud-
ies identiﬁed MATN1 and MATN3 among the most up-
regulated ECM proteins during chondrogenesis of MSCs in
micromass culture in the presence of TGF-b, dexametha-
sone, and bone morphogenetic protein (BMP)22,23. We have
shown that, while MATN1 is expressed by the post-mitotic
pre-hypertrophic chondrocytes in embryonic chickens24,
MATN3 is expressed by both proliferating and pre-hypertro-
phic chondrocytes25. This expression pattern suggests that
MATN1 orMATN3may play a role inmodulating chondrogen-
esis during the chondrocyte differentiation process.
Because of the tremendous up-regulation of MATN1 and
MATN3 during chondrogenesis, we hypothesize that
MATN1 or MATN3 may promote and facilitate in vitro carti-
lage formation of MSCs. In the present study, we tested thisFig. 1. (A) cDNA constructs of Matn1 and Matn3. (B) Safranin-O staining
TGF-b1. SFBs were either transfected with Matn1 cDNA (B1, B2, and B
A2, and A3). Samples at four time points are shown: day 0, day 3 (A1, B
The bar equalshypothesis by expressing MATN1 or MATN3 in primary
SFBs during chondrogenesis initiated by TGF-b1.Materials and methods
Cell culture reagents, including Dulbecco’s modiﬁed Eagle’s medium
(DMEM) and fetal bovine serum (FBS) were from Gibco (Grand Island,
NY, USA). Hoechst 33258 dye was from Polysciences (Warrington, PA,
USA). Dimethylmethylene blue dye was from Aldrich (Milwaukee, WI,
USA). TGF-b1 was from R&D Systems (Minneapolis, MN, USA). All other
reagents were from Sigma (St. Louis, MO, USA) unless otherwise speciﬁed.HARVEST OF SYNOVIAL TISSUEEach group of random biopsies of synovial tissue was obtained asepti-
cally from the knee joints of two pigs. The tissue was placed in cell culture
medium at room temperature and subjected to tissue digestion within 2 h
by following the reported method26. Brieﬂy, synovial tissue was ﬁnely
minced, digested for 30 min at 37C in phosphate-buffered saline (PBS) con-
taining 0.1% trypsin (Roche, Indianapolis, IN, USA) and thereafter digested
in 0.1% collagenase P (Roche, Indianapolis, IN, USA) in DMEM/10% FBS forwas used to evaluate chondrogenesis of SFB pellets induced by
3), or with Matn3 cDNA (C1, C2, and C3), or without any DNA (A1,
1, and C1), day 11 (A2, B2, and C2), and day 18 (A3, B3, and C3).
0.5 mm.
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and the cells were collected by centrifugation. Cells were kept in primary cul-
ture for 4 days (DMEM/10% FBS, 100 U/mL penicillin, 100 mg/mL streptomy-
cin, including removal of non-adherent cells on days 2 and 4) and
subsequently used for SFB isolation.NEGATIVE ISOLATION OF SFBsMixed populations of synovial cells (SCs) contain ﬁbroblasts, monocytes,
and macrophages. For negative isolation of SFBs from primary culture27, ad-
herent synovial cells were detached by short-term trypsinization for less than
1 min (0.25% trypsin/0.2% ethylenediaminetetraacetic acid EDTA, Gibco,
Grand Island, NY, USA) and 107/mL SCs were incubated with washed
4 107/mL Dynabeads M-450 CD14 (clone RMO52; Dynal Biotech, Oslo,
Norway) in PBS/2% FBS for 1 h at 4C on an orbital shaker. Dynabeads
CD14 are superparamagnetic polystyrene beads coated with a primary
monoclonal antibody (mAb) speciﬁc for the CD14 membrane antigen pre-
dominantly expressed on monocytes and macrophages. PBS/2% FBS was
then added to a ﬁnal volume of 10 mL and the conjugated cells (monocytes
and macrophages) and the unbound Dynabeads were collected using the
Dynal Magnetic Particle Concentrator (Dynal Biotech, Oslo, Norway). The
depleted supernatant with SFBs was transferred to a new tube for further
study.CLONING AND CONSTRUCTION OF MATN1 AND MATN3 cDNAsFull-length cDNAs of chicken Matn1 and mouse Matn3 were cloned by re-
verse transcription polymerase chain reaction (RT-PCR) from the RNA iso-
lated from sternal cartilage of 17-day-old chicken embryos and newborn
mice, respectively. Total RNA was isolated using the RNeasy Mini Kit (Qia-
gen, Valencia, CA, USA). RT-PCRs of Matn1 and Matn3 were performed in-
dividually using the Titan one tube RT-PCR system (Boehringer Mannheim,
Indianapolis, IN, USA) according to manufacturer’s instructions. The nucleo-
tide sequences of Matn1 and Matn3 cDNAs were conﬁrmed individually by
DNA sequencing. Those cDNAs were cloned into an expression vector
pcDNA3.1/V5-His (Invitrogen, Carlsbad, CA, USA).TRANSFECTION OF MATN1 AND MATN3 cDNAsSFBs were plated in DMEM containing 10% FBS at 1.8 106 cells/
25 cm2 tissue culture ﬂask (about 70e80% conﬂuent) the day before the Fu-
GENE 6 Reagent (Roche, Indianapolis, IN, USA) transfection experiment.
Transfection of Matn1 and Matn3 was performed in serum-free medium ac-
cording to the FuGENE 6 Reagent protocol from Roche. The optimal working
concentration was determined by using 8 mg of plasmid DNA and 12 mL of
FuGENE 6 Transfection Reagent. The monolayer SFBs were incubated in
the above mixture for 5 h, followed by the addition of FBS (the ﬁnal concen-
tration of FBS was 5%) overnight. The next day the medium was changed
into DMEM containing 10% FBS.PELLET TISSUE CULTURE SYSTEMAfter a 2-day incubation, SFBs transfected with Matn1 and Matn3 cDNAs
were detached individually by trypsinization with 0.25% trypsin/0.2% EDTA.
SFBs with mock transfection served as a control. The presence or absence
of vector DNA in mock transfections did not affect chondrogenesis of SFBs.
0.3 106 cells were centrifuged at 500g for 10 min in a 15 mL tube to form
a pellet. The pellets were cultured in 24-well plates (2 mL medium per
well) on a rotating shaker in a humid 5% CO2/95% air incubator with a deﬁned
medium, including High-Glucose DMEM, 40 mg/mL proline, 100 mM dexa-
methasone, 0.1 mM ascorbic acid 2-phosphate (Wako, Richmond, VA,
USA), 100 U/mL penicillin, 100 mg/L streptomycin, and 1 ITSþPremix [Col-
laborative Biomedical Products: insulin (6.25 mg/mL), transferrin (6.25 mg/
mL), selenous acid (6.25 mg/mL), and linoleic acid (5.35 mg/mL), with bovine
serum albumin (1.25 mg/mL)] with the supplementation of 10 ng/mL TGF-b1.
SFBs without TGF-b1 treatment served as a control. The medium was
changed every other day. The time points were days 0, 3, 11, and 18.HISTOLOGY AND IMMUNOHISTOCHEMISTRYRepresentative pellets (n¼ 3 specimens per data point) were ﬁxed for
24 h at 4C in 4% paraformaldehyde in PBS (pH 7.4), dehydrated in a series
of ethanols, cleared in xylene, embedded in parafﬁn, and sectioned to 5 mm.
The sections were stained with safranin-O/fast green for GAG and counter-
stained with hematoxylin for the nucleus. The percentage of safranin-O pos-
itive areas was quantiﬁed under the microscope using NIH Imagine J.
Immunohistochemistry was carried out using the Histostain-SP Kits
(Zymed, San Francisco, CA, USA). Endogenous peroxidase was blockedby treating the sections with 1% hydrogen peroxide in methanol for 30 min.
The sections were digested by 2 mg/mL hyaluronidase for 30 min. Nonspe-
ciﬁc protein binding was blocked by incubation with 10% normal goat serum.
The sections were incubated in afﬁnity-isolated IgG fractions of monoclonal
mouse antibody against chicken MATN1 (1:200, 1H1) at 4C overnight. The
negative control sections were incubated with 0.01 M PBS. Thereafter, the
sections were treated sequentially with ready-to-use biotinylated secondary
antibody and streptavidin conjugate (Invitrogen), followed by standardized
development in diaminobenzidine (Invitrogen). The sections were counter-
stained with hematoxylin.BIOCHEMICAL ANALYSES AND WESTERN BLOTRepresentative pellets (n¼ 3 specimens per data point) were digested for
4 h at 60C with 125 mg/mL of papain in phosphate based EDTA buffer
(100 mM phosphate, 10 mM EDTA, pH 6.5) containing 10 mM cysteine.
DNA content was measured with the use of Hoechst 33258 dye and a spec-
troﬂuorometer (QM-1; Photon Technology International, South Brunswick,
NJ, USA) with type I calf thymus DNA (Sigma) as a standard. GAG amount
was measured by using dimethylmethylene blue dye28 and a spectrophotom-
eter (PerkineElmer, Norwalk, CT, USA) with bovine chondroitin sulfate as
a standard. Western blot analysis was performed using standard protocols.
The primary antibodies used were a mAb against collagen II (diluted
1:200, NeoMarkers, Fremont, CA, USA), and a mAb against V5 (diluted
1:5000, Invitrogen). Horseradish peroxidase conjugated goat anti-mouse or
goat anti-rabbit IgG (Hþ L) (Bio-Rad Laboratories, Melville, NY, USA), di-
luted 1:5000, was used as a secondary antibody.RNA ISOLATION AND REAL-TIME QUANTITATIVE RT-PCRTotal RNAwas extracted from pellets by homogenizing using anRNase-free
pestle in TRIzol Reagent (Life Technologies, Inc., Grand Island, NY, USA) and
RNeasy Mini Kit (Qiagen, Valencia, CA, USA) according to manufacturer’s in-
structions. RNAs were used for oligo(dT)12e18-primed cDNA synthesis using
SuperScript II RT (Invitrogen, Carlsbad, CA, USA). Quantiﬁcation of mRNAs
was performed by real-time quantitative RT-PCRwith DyNAmo SYBRGreen
qPCRKit andDNAEngineOpticon system (MJResearch, Inc.,Waltham,MA,
USA). Several gene markers of pig species were focused on, including
aggrecan gene (forward primer is TGCAGGTGACCATGGCC and reverse
primer is CGGTAATGGAACACAACCCCT), collagen I gene (forward primer
is CTGGTGATGCTGGTCCTGTTG and reverse primer is CCTTGGGGTT
CTTGCTGATGT), collagen II gene (forward primer is CCGCCTTTGC
TGGCTTAGGCCCG and reverse primer is CCACCATTGATGGTTTCTC
CAAACC), collagen X gene (forward primer is ACGGGCAACAGCACTAT
GACC and reverse primer is GCACTCCCTGAAGCCTGATCC), and Sox 9
gene (forward primer is GTGCTCAAGGGCTACGACTGG and reverse primer
is CCGCTTCTCGCTCTCATTCAG). The cycle parameters were 95C for
10 min to activate the Tbr DNA polymerase, then 39 cycles at 94C for 10 s
denaturation, followed by 55C for 20 s annealing and 72C for 20 s extension.
The last extension was 72C for 5 min. The 18S RNA (forward primer is
CGGCTACCACATCCAAGGAA and reverse primer is GCTGGAATTACC
GCGGCT) was ampliﬁed at the same time and used as an internal control.
The cycle threshold (Ct) values for 18S RNA and that of samples were
measured and calculated by computer software (PerkineElmer, Wellesley,
MA, USA). Relative transcript levels were calculated as x¼ 2DDCt, in which
DDCt¼DEDC, and DE¼CtexpCt18s; DC¼Ctct1Ct18s29.STATISTICAL ANALYSESStatistics was assessed by one-way analysis of variance (ANOVA);
P values less than 0.05 were considered statistically signiﬁcant.ResultsIN VITRO CHONDROGENESIS OF SFBsTo study chondrogenesis of SFBs, we incubated puriﬁed
SFBs in a pellet culture under serum-free conditions in
a chemically deﬁned medium with or without the supplemen-
tation of 10 ng/mL TGF-b1 for 18 days. In a parallel set of ex-
periments, SFBs were transfected with a full-lengthMatn1 or
Matn3 cDNAbefore culture incubation. Thepellet culturewas
refreshed with medium containing TGF-b1 every other day in
TGF-b1 supplementation groups. The SFB pellets were col-
lected for histological, biochemical, and molecular analysis
during the incubation period at days 0, 3, 11, and 18.
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CHONDROGENESIS OF SFBsHistological analysis was performed with safranin-O that
stains highly sulfated cartilage proteoglycans [Fig. 1(B)]. It
indicated that SFBs underwent chondrogenesis in the pe-
ripheral regions of the pellet after 3 days incubation in the
presence of TGF-b1 [Fig. 1(B, A1)]. However, chondrogenic
differentiation of SFBs was reduced by day 11 [Fig. 1(B,
A2)], and further diminished by day 18 [Fig. 1(B, A3)], de-
spite the presence of TGF-b1.
In contrast to the control SFBs, the SFBs expressing
MATN1 or MATN3 maintained chondrogenesis throughout
the incubation period [Fig. 1(B, B1, B2, B3, and C1, C2,
C3)]. Furthermore, both the overall sizes of the pellet and
the chondrogenic areas in the pellet were larger in SFBs ex-
pressing MATN1 or MATN3 than in control SFBs [Fig. 1(B)].
Quantitative microscopic analysis indicated that while the
safranin-O positive areas decreased gradually in control
SFB pellets during the incubation period, SFB pellets ex-
pressing MATN1 or MATN3 increased their chondrogenic
areas from day 3 to day 11, and maintained their chondro-
genic areas from day 11 to day 18 [Fig. 2(A)].
Biochemical analysis indicated that the total amount of
sGAG in the control SFB pellet decreased from day 3 to
day 11, and from day 11 to day 18 during the incubation pe-
riod [Fig. 2(B)]. However, the total GAG amount increased in
MATN1 or MATN3 expressing SFBs from day 3 to day 11,
and maintained from day 11 to day 18 during the incubation
period. Biochemical quantiﬁcation of the total DNA amount
per pellet indicated that the cell number in all SFB pellets
decreased over the incubation period [Fig. 2(C)]. However,
the SFB pellets expressing MATN1 or MATN3 consistently
contained more than 20% of cells than the control SFBs.MOLECULAR ANALYSIS OF CHONDROGENIC MARKERSFig. 2. Enhancement of chondrogenesis by the expression of
MATN1 or MATN3 in SFB pellet culture. (A) Quantiﬁcation of the
percentage of safranin-O positive areas in SFB pellet sections.
*Signiﬁcantly higher than the corresponding control group,
*P< 0.05, **P< 0.01, and ***P< 0.001. Error bars represent the
mean  standard deviation (SD) for n ¼ 5. (B) Compared to
the control, expression of either MATN1 or MATN3 increased the
amount of GAG within the SFB pellets at day 11 and day 18. (C)
Expression of MATN1 or MATN3 and increased the DNA content
(cell number) in the SFB pellets throughout the incubation period.
*Signiﬁcantly higher than the corresponding control group,
*P< 0.05, **P< 0.01, and ***P< 0.001. Error bars represent the
meanSD for n¼ 4.To determine the effect of MATNs on chondrogenesis of
SFBs at the molecular level, we quantiﬁed the protein levels
of MATNs and type II collagen using western blot analysis.
Expression of MATN1 and MATN3 was demonstrated by
the positive identiﬁcation of recombinant MATNs in MATN1
or MATN3 expressing SFBs [Fig. 3(A)]. The level of type II
collagen was higher in MATN1 or MATN3 expressing cells
than that from control cells [Fig. 3(B, D)]. In contrast, the
levels of housekeeping protein b-actin remain constant
[Fig. 3(C)]. Immunohistochemical analysis using a mAb
against MATN1 showed MATN1 was distributed throughout
the pellet in MATN1 expressing SFBs [Fig. 3(E)].
Next, we quantiﬁed the relative mRNA levels of chondro-
genic markers including collagen type II (a1), aggrecan core
protein, and Sox 9 using real-time quantitative RT-PCR.
The mRNA levels of all three chondrogenic markers were
dramatically increased in MATN1 or MATN3 expressing
SFBs than in control SFBs on day 11, although they were
similar among different groups on day 3 and day 18
[Fig. 4(AeC)]. The extent of stimulation was different be-
tween MATN1 and MATN3 expressing cells, with MATN1
expressing cells exhibiting a higher extent of stimulation
for chondrogenic markers. The extent of stimulation for
chondrogenic markers by MATN1 and MATN3 was reduced
in day 18 samples. The same trend existed to a smaller
extent for the mRNA level of hypertrophic chondrocyte
marker collagen type X (a1) [Fig. 4(D)]. In contrast, only
a small difference (<twofold) was observed among different
SFB groups for the ﬁbroblast marker collagen type I (a1)
[Fig. 4(E)].MATN ENHANCEMENT OF SFB CHONDROGENESIS IS TGF-b1
DEPENDENTTo study the effect of TGF-b in combination with MATNs in
SFB chondrogenesis, we carried out two parallel SFB pellet
culture incubations either in the presence or absence of
10 ng/mL TGF-b1. In the absence of TGF-b1 treatment, the
GAG amount per pellet decreased 77.8% from day 3 to day
11, and decreased 33.3% from day 11 to day 18. Expression
of MATN1 or MATN3 in SFBs could not reverse this trend
[Fig. 5(A)]. In the presence of TGF-b1 treatment, the GAG
amount in the control group was decreased 4.3% from day
3 to day 11, and decreased 38.6% per pellet from day 11 to
day 18 [Fig. 5(B)]. However, inMATN1 orMATN3 expression
groups, the GAG amount increased 23% per pellet from day
3 to day 11 and maintained this level from day 11 to day 18.
Fig. 3. Western blot analysis of expression levels of MATNs (A) and collagen type II (B) in the pelleted SFBs transfected with either MATN1 or
MATN3 at day 11. b-Actin served as an intrinsic housekeeping protein (C). An equal amount of protein was loaded in each lane. The relative
value of collagen II protein level was adjusted against the protein level of b-actin (D). The adjusted value of collagen II protein level in control
samples was set as 1 unit. All data shown were typical of those obtained from three independent experiments. MATN1 expression (a, b) in the
transfected pellets was also shown as brown color diaminobenzidine (DAB) by immunostain (E), while the non-transfected pellets served as
a control (c, d). The bar equals 0.5 mm.
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(DNA amount per pellet) decreased 78.8% from day 3 to
day 11, and decreased 50% from day 11 to day 18
[Fig. 5(C)]. The MATN1 or MATN3 expression groups
exhibited the same extent of cell number decrease as the
control group [Fig. 5(C)]. In the presence of TGF-b1, the
cell number per pellet for the control group decreased52.9% from day 3 to day 11 and another 33.3% from day
11 to day 18 [Fig. 5(D)]. In comparison, the cell number
per pellet in MATN1 or MATN3 expressing SFBs decreased
only 43% from day 3 to day 11 and only 11.4% from day 11
to day 18. Taken together, these data suggest that the pro-
chondrogenic effect of MATNs on SFB proliferation and
differentiation is dependent on the presence of TGF-b1.
Fig. 4. Real-time RT-PCR analysis of chondrogenic markers Col II (A), aggrecan (B), and Sox 9 (C), and hypertrophic chondrocyte marker Col
X (D), and ﬁbroblast marker Col I (E). Compared to the control at day 3, expression of either MATN1 or MATN3 resulted in higher levels of
mRNAs encoding collagen type II, aggrecan, and Sox 9 at day 11. Every mRNA value has been adjusted against the housekeeping 18S RNA.
The adjusted mRNA level of the control sample at day 3 was set as 1 unit. All data shown were typical of those obtained from three indepen-
dent experiments.
Fig. 5. Enhancement of chondrogenesis by the expression of MATN1 or MATN3 in SFB pellet culture requires the presence of TGF-b1. The
amount of GAG (A and B) and the amount of DNA (C and D) were quantiﬁed within the SFB pellets either in the absence of TGF-b1 (A and C),
or in the presence of TGF-b1 (B and D). *Signiﬁcantly different than the corresponding day 3 group, *P< 0.05, **P< 0.01, and ***P< 0.001.
Error bars represent the meanSD for n¼ 4.
1115Osteoarthritis and Cartilage Vol. 16, No. 9
1116 M. Pei et al.: Matrilins enhance chondrogenesisDiscussion
Chondrocytes are prone to de-differentiation to ﬁbro-
blasts, especially under in vitro culture conditions. This
poses a signiﬁcant challenge to tissue engineering of
stem cells for chondrogenesis. In this study, we show that
initiation and maintenance of chondrogenesis of SFBs in
vitro require both TGF-b1 treatment and the expression of
cartilage matrix protein MATN1 or MATN3. Our study
reveals that the actions of TGF-b1 and MATNs depend on
each other and that they may play different roles during
chondrogenesis of SFBs.
Treatment with TGF-b1 alone initiates chondrogenesis,
but is not sufﬁcient to maintain chondrogenic differentiation
of SFBs without the expression of MATN1 or MATN3. A
previous study has shown that TGF-b1 induces in vitro car-
tilage formation from MSCs5. We show that TGF-b1 at
10 ng/mL induced chondrogenesis in the peripheral region
of the SFB pellet. This is a concentration dependent phe-
nomenon, since TGF-b1 at higher concentrations (e.g.,
30e40 ng/mL) induced chondrogenesis throughout the
pellet27. However, SFBs incubated in TGF-b1 at higher con-
centrations also had less DNA content in the pellet27. Sub-
sequent investigations have also shown that TGF-b alone is
not sufﬁcient to fully differentiate MSCs into chondro-
cytes12,30. Other growth factors such as BMPs, in particular
BMP-2, are necessary for the chondrogenic differentiation
process10. It is not clear why other factors in addition to
TGF-b are required to sustain the differentiation process,
but one of the possible mechanisms is to provide a carti-
lage-speciﬁc ECM environment to facilitate the chondro-
genic differentiation process31.
We showed that the exogenous expression of MATN1 or
MATN3, two ECM proteins expressed speciﬁcally in devel-
oping cartilage during endochondral bone formation25,32,33,
not only maintains but also enhances SFB chondrogenesis
initiated by TGF-b. This role may occur in the three periods
of in vitro chondrogenesis of SFBs. In the early period (day
0e3 of pellet culture incubation), the presence of MATN1 or
MATN3 increases the cell number per pellet to 120% of the
control group [Fig. 2(C)]. This difference of cell number is
maintained throughout the entire pellet culture period
[Fig. 2(C)]. Thus, MATNs increase the cell number during
the early period of chondrogenesis. In the middle period
(between day 3 and day 11), the presence of MATN1 or
MATN3 increases the total GAG amount per pellet to
136% of the control group [Fig. 2(B)]. Molecular analysis us-
ing real-time RT-PCR and western blot indicate that the
synthesis of chondrogenic markers including aggrecan, col-
lagen II, and Sox 9 is increased in the MATN expressing
SFB groups on day 11 (Figs. 3 and 4), which is supported
by the data from the histological and biochemical analysis
of chondrogenesis (Figs. 1 and 2). Thus, MATNs enhance
expression of chondrogenic markers during this stage. In
the late period (between day 11 and day 18), there is
a sharp decline of the GAG amount and the cartilage pro-
teoglycan-positive areas in the control group pellets. How-
ever, in MATN expressing pellets, the levels of the GAG
amount and the cartilage proteoglycan-positive areas
remain constant between day 11 and day 18 (Figs. 1 and
2). Therefore, MATNs maintain chondrogenesis of SFBs
in the late stage.
We have shown that enhancement and maintenance of
SFB chondrogenesis by MATN1 and MATN3 are critically
dependent on the presence of TGF-b1. Without TGF-b, nei-
ther MATN1 nor MATN3 can stimulate chondrogenesis by
itself. Thus, we established a co-requirement of a growthfactor (TGF-b) and a cartilage ECM molecule (MATN1 or
MATN3) during in vitro chondrogenesis of SFBs. There
are at least two possible mechanisms to explain why
MATNs are required in chondrogenesis initiated by TGF-
b. The ﬁrst is their structural role and the second is their reg-
ulatory role in cartilage ECM.
MATNs are putative adaptor proteins of the ECM in which
they form both collagen dependent and independent ﬁla-
mentous networks34. MATN1 and MATN3 have been
shown to stabilize the cartilage matrix structure by forming
a ﬁlamentous network to connect different types of matrix
ligands. MATNs interact with collagen type II, type IX,
aggrecan, small proteoglycans, COMP, and integrin
a1b135,36. Thus, the presence of MATN1 or MATN3 may
maintain the chondrogenic phenotype of differentiated
SFBs by stabilizing cartilage-speciﬁc matrix structures. Pre-
vious studies have shown that adhesiveness to various
ECMs determines the differentiation of embryonic stem
cells in such a way that efﬁcient cellecell aggregation,
together with less efﬁcient cell attachment and spreading,
results in more efﬁcient cell differentiation37.
MATNs may also play a regulatory role in chondrogenesis
of SFBs by sustaining the transduction of TGF-b signals to
these cells. It has been shown previously that ECM in carti-
lage may serve as a matrix reservoir of TGF-b. For example,
small proteoglycans such as biglycan and decorins bind
TGF-b thereby modulating its biological effects38,39. Al-
though it is not known whether TGF-b is a ligand of the
MATN family, MATNs have been demonstrated to interact
with small proteoglycans that bind TGF-b35, which may in
turn affect TGF-b signaling. Thus, MATNs may enhance
the availability of TGF-b to the cells by regulating its presence
in the pellet matrix during chondrogenesis of SFBs. These
possible mechanisms remain to be tested in future studies.
In summary, our ﬁnding that MATN1 and MATN3 en-
hance and maintain chondrogenesis of SFBs induced by
TGF-b supports the hypothesis that not only the inductive
growth factors, but also the conductive ECM may be
required for sustaining chondrogenic differentiation of
MSCs. It reveals a novel function of MATN1 and MATN3
in modulating chondrogenesis of SFBs. It may have strong
implications for the successful utilization of tissue engineer-
ing for inducing and maintaining cartilage formation from
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